Acadia to raise $86.4M for second Phase III pimavanserin trial

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) plans to raise $86.4 million in a private placement through the sale of 19 million shares at $4.43 and seven-year warrants to purchase 500,000 shares at $4.42 per warrant. Each warrant is exercisable at $0.01. Jefferies and Cowen are lead placement agents. JMP Securities is co-placement agent. Acadia was up $0.58 to $5.01 on Wednesday. ...